


Innovent, Shenogen to evaluate combination therapy for advanced cancer

07 August 2019 | News

Evaluate the combination therapy of Innovent's Tyvyt® (Sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody with Shenogen's SNG1005, in patients with advanced cancer



Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, has announced the signing of a collaboration agreement with Shenogen Pharma Group Ltd. to evaluate the combination therapy of Innovent's Tyvyt[®] (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody with Shenogen's SNG1005, in patients with advanced cancer.

SNG1005 is a conjugate of angiopep-2 and paclitaxel that Shenogen licensed from overseas. Multiple Phase II clinical trials have been completed in the United States (U.S.), and its Phase III clinical trial protocol has been approved by the U.S. Food and Drug Administration (FDA). Shenogen has full development and commercialization rights for SNG1005 in Greater China. Currently, the Investigational New Drug (IND) application of Phase II/III clinical trial for the treatment of breast cancer carcinoma brain metastases (BCBS) in China has been approved by the National Medical Products Administration (NMPA), and the clinical trial is planned. Tyvyt® (sintilimab Injection) is the anti-PD-1 inhibitor co-developed by Innovent and Eli Lilly and Company (Lilly). On 24 December 2018, Tyvyt® (sintilimab Injection) was granted approval for market authorization by the NMPA for the treatment of patients with classical Hodgkin's lymphoma (cHL) that has relapsed or refractory (r/r) after two or more lines of systemic chemotherapy (r/r cHL).

Dr Kun Meng, Chairman of Shenogen, commented, "The combined therapy of immune checkpoint inhibitors and anti-tumour therapeutics has become the standard approach for the development of anti-tumour treatments. We are looking forward to closing cooperation with Innovent in exploring the potential efficacy of anti-PD-1 inhibitor in combination with SNG1005. We are expecting the underlying synergistic effect in various cancers."

"SNG1005 is a first-in-class nab-paclitaxel therapeutic in development that can pass through the blood-brain barrier (BBB), and we are very pleased to cooperate with Shenogen to explore the clinical synergistic efficacy with our PD-1 inhibitor. We hope to bring more clinical benefits to patients with advanced carcinomas," said Dr Hui Zhou, Vice President and Head of Oncology Strategy and Medical Sciences of Innovent.